Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Debt to Equity: 2016-2025

Historic Debt to Equity for Myriad Genetics (MYGN) over the last 7 years, with Sep 2025 value amounting to $0.32.

  • Myriad Genetics' Debt to Equity rose 501.40% to $0.32 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.32, marking a year-over-year increase of 501.40%. This contributed to the annual value of $0.06 for FY2024, which is 14.90% up from last year.
  • Myriad Genetics' Debt to Equity amounted to $0.32 in Q3 2025, which was up 109.43% from $0.15 recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Debt to Equity ranged from a high of $0.32 in Q3 2025 and a low of $0.05 during Q4 2023.
  • Over the past 3 years, Myriad Genetics' median Debt to Equity value was $0.05 (recorded in 2023), while the average stood at $0.09.
  • Its Debt to Equity has fluctuated over the past 5 years, first spiked by 3,316.48% in 2021, then fell by 5.39% in 2024.
  • Quarterly analysis of 4 years shows Myriad Genetics' Debt to Equity stood at $0.12 in 2021, then reached $0.05 in 2023, then increased by 14.90% to $0.06 in 2024, then skyrocketed by 501.40% to $0.32 in 2025.
  • Its last three reported values are $0.32 in Q3 2025, $0.15 for Q2 2025, and $0.08 during Q1 2025.